The shadow of generic challenges has long loomed above copyright’s iconic drug, Sildenafil, triggering questions about the outlook of similar drug ventures. While initial periods saw impressive returns, the patent expiration has created the way for discounted copies, possibly diminishing revenue and presenting a real risk for stakeholders looking